Despite that grade III astrocytomas have always been considered to be high-grade tumors and treated as glioblastomas (GBMs), the mutate IDH group was reported to show overall survival (OS) comparable to corresponding grade II tumors [23]. This evidence concerns the gene IDH1 and glioblastoma.